GX Acquisition Corp

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

The SPAC closed its merger with clinical-stage biotech Celularity.

Why GX Acquisition Stock Soared Today

Palantir Technologies

GXGX's merger announcement is causing the stock to soar this afternoon. The SPAC is merging with biotech play Celularity.

GXGX Merger: The SPAC News That Has GXGX Stock Soaring

Celularity

Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021

Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update

NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an amendment to GX's amended and restated certificate of incorporation to extend the date by which GX must effectuate its initial business combination  from May 23, 2021 to July 31, 2021. As previously disclosed, on January 8, 2021, GX entered into a Merger Agreement and Plan of Reorganization (the "Merger Agreement") with Celularity Inc. ("Celularity"), Alpha First Merger Sub, Inc. and Alpha Second Merger Sub, LLC.

GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal

NEW YORK, May 10, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, today reaffirmed its intention to support the proposal to amend GX's amended and restated certificate of incorporation to extend the date by which GX must complete its initial business combination from May 23, 2021 to July 31, 2021 (the "Extension" and such later date, the "Extended Date"). This proposal will be voted on by stockholders at the upcoming special meeting of stockholders on May 14, 2021.

GX Acquisition Corp. Announces Additional Contributions to Trust Account

NEW YORK, April 16, 2021 /PRNewswire/ -- On April 14, 2021, GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information regarding a proposal to amend GX's amended and restated certificate of incorporation (the "Charter") to extend the date by which GX has to complete its initial business combination (the "Extension") from May 23, 2021 to July 31, 2021. The Charter currently provides that GX has 24 months from the closing of its initial public offering (until May 23, 2021) to complete an initial business combination, which is customary for a special purpose acquisition company like GX.

GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination

Agba Acquisition Ltd

Alussa Energy Acquisition Corp

CF Finance Acquisition Corp. III

Fortress Value Acquisition Corp. II

Gores Holdings V, Inc

The stock market has suddenly broken to the downside over the past two weeks. That makes these SPACs particularly risky bets as the momentum fades.

7 Upcoming SPAC Mergers to Avoid

News for GX Acquisition Corp Stock (GXGX)